FLT3 and acute myeloid leukemia: However, strategies such as disrupting Wnt/β-catenin signals or combining Pim-1 kinase inhibitors or PP2A activators with FLT3 inhibitors synergize and promote their anti-leukemic effects in AML [648–650].